FDA gives Zydus OK for fludrocortisone acetate tablets
Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
Zydus recently received the Food and Drug Administration’s green light for fludrocortisone acetate tablets, 0.1 mg.
Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
[Read more: Zydus obtains FDA nod for generic Sabril]
Fludrocortisone acetate tablets will be produced at the group’s manufacturing site at Moraiya, Ahmedabad.
Fludrocortisone acetate tablets had a market value of $19.9 million, per IQVIA July 2024 data.
[Read more: Zydus launches generic Myrbetriq]